Back to News
Market Impact: 0.25
HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth?
Source: Nasdaq
Healthcare & BiotechCompany FundamentalsProduct Launches
Harmony Biosciences shares gained 27.6% over six months as Wakix sales surged and its pipeline advanced. New formulations and clinical milestones are described as additional growth opportunities; the article provides no sales figures or specific milestone details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
HRMY0.60
More News
- Why did CoreWeave stock get crushed this week? Look to this corner of the debt market for clues
- AI stock sell-off ramps up over debt-fueled data center spending fears: ‘Full-blown crisis of confidence'
- All the news about the iPhone Duo
- The Tesla Roadster should go into production in 2028, but don't get your hopes up
- Apple’s $1,999 iPhone Duo puts the company's status-symbol power to the test
- Yields continue to rattle investors. These sectors are most at risk if rates stay elevated